Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib disminuye la producción de endotrofina (PRO-C6), un mediador de fibrosis e inflamación

Tuesday, March 10, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Seralutinib has been shown to decrease the production of endotrophin (PRO-C6), which plays a significant role in fibrosis and inflammation. This reduction could have positive implications for patients suffering from conditions associated with these processes. The findings suggest a potential therapeutic benefit of Seralutinib in managing related diseases.
Price reaction · baseline $0.5553 (2026-03-09 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
-8.7%
day 1
-11.7%
day 3 · peak
-21.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib effectively reduces endotrophin production.
  • Endotrophin is a key mediator of fibrosis and inflammation.
  • Potential for improved patient outcomes in related conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib disminuye la producción de endotrofina (PRO-C6), un mediador de fibrosis e inflamación
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib?

Seralutinib is a therapeutic agent that targets conditions related to fibrosis and inflammation.

How does Seralutinib affect endotrophin?

Seralutinib decreases the production of endotrophin, which is involved in fibrosis and inflammation.

What is the significance of endotrophin?

Endotrophin (PRO-C6) is a mediator that plays a crucial role in the processes of fibrosis and inflammation.

What conditions could benefit from Seralutinib?

Conditions associated with fibrosis and inflammation may see therapeutic benefits from Seralutinib.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib endotrophin fibrosis inflammation
Last updated: Mar 10, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →